A paper detailing the clinical trial of a physician-initiated clinical study using injectable cell scaffold (ICS-001) for comprehensive angiogenesis therapy for severe chronic lower limb ischemia (...
A paper detailing the details of a physician-initiated clinical trial of comprehensive, severe chronic lower limb ischemia (CLTI) angiogenesis therapy using Injectable cell scaffold (ICS-001), led by CEO Kenichi Yamahara, has been published in BMJ Open. This clinical trial has now completed enrollment for all planned cases and is scheduled to conclude in July of next year. The trial results are expected to be released in the latter half of next year. https://bmjopen.bmj.com/c
Oct 23, 2025
Certified as a venture company originating from Hyogo College of Medicine.
当社が兵庫医科大学発ベンチャー企業に認定されました。兵庫医科大学は当社代表取締役山原研一が所属し、同病院は Injectable cell scaffold (ICS-001) を用いた包括的高度慢性下肢虚血（CLTI）向け血管新生療法についての医師主導治験の治験実施医療機...
Oct 1, 2025